Navigation Links
US Army Study Shows STB Lifesaving Technology's® FAST® Dressing Superior to the Most Effective Currently Available Agents for Controlling Arterial Bleeding
Date:1/27/2011

ROCKVILLE, Md., Jan. 27, 2011 /PRNewswire/ -- In a study conducted jointly by the US Army Institute of Surgical Research and STB Lifesaving Technologies®, and just published in The Journal of Trauma, STB®'s FAST® (Fibrin Adhesive STat) Dressing was shown to be superior to the most effective available agents for controlling severe arterial bleeding.

The study compared currently available agents with the FAST® dressing, in a coagulopathic hemorrhage model simulating a gunshot wound to a major peripheral artery.  The FAST® dressing produced significantly better outcomes (higher survival rate, longer survival time, higher incidence of stable hemostasis and less blood loss).  STB®'s FAST® dressing was the only agent that stopped bleeding and prevented exsanguination in most subjects.

"The consistently better results obtained using the FAST® Dressing reflect the results of applying the unique FAST® technology to this most challenging bleeding problem. The ability to optimally mix the fibrinogen and thrombin components during manufacture results in a hemostatic product of unprecedented effectiveness, flexibility and ease of handling. This technology is unaffected by the coagulation state of the patient and therefore functions when other types of products cannot. This has significant implications for the treatment of both military and civilian casualties," commented Dr. Martin MacPhee, STB®'s Chief Scientific Officer.

The report emphasizes the urgent need for methods such as this to control hemorrhage in the field and operating rooms to potentially reduce war mortality, as uncontrolled bleeding remains the leading cause of potentially preventable death in combat casualties.  Hemorrhage is also a leading cause of death in civilian trauma patients.

"Study after study has confirmed the faith we have in our product's ability to save lives, and it's why we refer to our technology as 'A Breakthrough for Life.' Test results such as this recent report demonstrate why the Army continues to support for our research, assisting us in accelerating the step-up to cGMP manufacturing, and the necessary work required to file for FDA approval to initiate human clinical trials," said Richard Moscarello, STB®'s CEO.  

About STB®  

Founded in 2005, STB Lifesaving Technologies® (STB®) is a privately held, pre-clinical stage, biotechnology development company located in Rockville, Maryland. STB® is focused on developing a comprehensive suite of products to stop serious and life threatening bleeding in trauma and surgical settings. With a strong proprietary position using its all-natural, patented FAST® technology platform, STB®'s products will be indispensable to both the military and civilian medical markets.


'/>"/>
SOURCE STB Lifesaving Technologies
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cetero Research Announces Completion of 20,000th Early-Phase Clinical Study
2. Surgeons at University of California San Diego Perform 1st TRAM Flap Procedure in an International Multi-Center Study Using TIGR® Matrix Surgical Mesh, the Worlds 1st Long-Term Resorbable Mesh
3. Generex to Increase Patient Enrollment of its Phase II Breast Cancer Vaccine Study
4. R-Tech Ueno Completes Phase 2a Clinical Study of RK-023 to Treat Androgenetic Alopecia
5. Pervasis to Present Interim Data from Phase 1/2 Clinical Study of Novel Cell Therapy Targeting Peripheral Artery Disease at International Conference on Cell Therapy for Cardiovascular Diseases
6. NIH-Funded Study Is First to Demonstrate Increased Long-Term Survival With Favorable Neurologic Function Among Patients Receiving CPR Using ACSI ResQPump® and ResQPOD® CPR Devices
7. CVS Caremark Study Evaluates Which Pharmacy Channel Consumers Choose When Given Choice of Mail or Retail Prescriptions
8. New Study on HIV/AIDS Redefines the Size, Scale, and Scope of Epidemic
9. Groundbreaking Study Showed Bayers Advantage Multi® for Dogs (imidacloprid + moxidectin) Topical Solution was the only Heartworm Preventive Tested That Demonstrated 100 Percent Efficacy against the Challenging MP3 Strain
10. Pacira Pharmaceuticals Presents New Data from EXPAREL Phase 3 Study at Orthopaedic Research Societys 57th Annual Meeting
11. Long Term Care Pharmacy Alliance Concerned with Proposed CMS Rule; New Study Confirms LTCPA Position
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2017)... 18, 2017 EpiVax, Inc. ("EpiVax") ... and immune engineering, today announced a new ... (H7N9) vaccine. ... influenza and presents a challenge for traditional ... to be effective. Using state-of-the-art bioinformatics and molecular ...
(Date:9/12/2017)... YORK , Sept. 12, 2017   EcoVadis , the leading ... has published the first annual edition of its Global CSR Risk and ... companies evaluated by EcoVadis, based on Scorecard Ratings that analyzed nearly 800,000 ... ... Index ...
(Date:9/12/2017)... 12, 2017  ValGenesis Inc., the global leader ... pleased to announce the appointment of Dr. ... Board of Directors and Chairman of Advisory Board ... science companies to manage their entire validation lifecycle ... in this process. Furthermore, ValGenesis VLMS enables rigorous ...
Breaking Medicine Technology:
(Date:9/20/2017)... ... September 20, 2017 , ... In just a short time ... already been receiving positive feedback from customers trying the product for the first time, ... Brain Booster was developed by neurosurgeon Shawn Moore, MD, for everyone from athletes at ...
(Date:9/20/2017)... ... September 20, 2017 , ... The Centers for Medicare and ... that it will transition to using only Worksheet S-10 to distribute Disproportionate Share Hospital ... three live 60-minute complimentary webinars on October 17, 2017 at 2 P.M. ...
(Date:9/20/2017)... ... September 20, 2017 , ... Recognising that in today’s busy ... Greeny delivers positive results in just three weeks. Setting the groundwork for a ... Fitting seamlessly into hectic work and family schedules, participants can lose up to ...
(Date:9/20/2017)... ... , ... “Finn Mouseson”: follows the exciting story of a mouse as the ... out on a journey that will show that friends are to be gathered but ... author and illustrator, Melody Gersonde-Mickelson, who has earned a bachelor’s degree in Fine Arts ...
(Date:9/20/2017)... , ... September 20, 2017 , ... “Psalms of Humidity”: ... peace of mind and move the readers one step closer to God. “Psalms of ... realized that his mistakes that have been made within his life are the very ...
Breaking Medicine News(10 mins):